Zenas BioPharma (NASDAQ:ZBIO) Price Target Raised to $21.00 at Morgan Stanley

Zenas BioPharma (NASDAQ:ZBIO) had its price target upped by Morgan Stanley from $19.00 to $21.00 in a report issued on Tuesday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

A number of other research analysts have also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday, February 10th. Wedbush restated an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research report on Monday, December 22nd. Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Evercore assumed coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 target price for the company. Finally, Jefferies Financial Group reissued a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Zenas BioPharma has a consensus rating of “Moderate Buy” and a consensus price target of $44.14.

Zenas BioPharma Price Performance

ZBIO stock opened at $23.48 on Tuesday. The company has a 50 day simple moving average of $22.78 and a 200 day simple moving average of $27.18. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -3.01 and a beta of -1.94. Zenas BioPharma has a 1 year low of $6.11 and a 1 year high of $44.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Activity at Zenas BioPharma

In other Zenas BioPharma news, Director Patricia L. Allen bought 4,160 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was acquired at an average price of $26.36 per share, with a total value of $109,657.60. Following the completion of the purchase, the director directly owned 19,860 shares of the company’s stock, valued at approximately $523,509.60. This trade represents a 26.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Hongbo Lu purchased 25,985 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was acquired at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the purchase, the director owned 347,968 shares of the company’s stock, valued at approximately $7,829,280. This trade represents a 8.07% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 202,845 shares of company stock worth $3,747,185 in the last 90 days. Corporate insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. SR One Capital Management LP grew its holdings in Zenas BioPharma by 2.6% in the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after purchasing an additional 126,315 shares during the period. NEA Management Company LLC raised its holdings in shares of Zenas BioPharma by 28.9% during the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after purchasing an additional 789,500 shares during the period. Federated Hermes Inc. raised its holdings in shares of Zenas BioPharma by 45.9% during the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares during the period. Vanguard Group Inc. boosted its position in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after purchasing an additional 290,307 shares in the last quarter. Finally, Polar Capital Holdings Plc bought a new position in shares of Zenas BioPharma during the 4th quarter worth about $38,402,000.

Trending Headlines about Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company secured up to $250M of non-dilutive, multi‑tranche debt financing and reiterated near-term regulatory milestones (FDA filing for obexelimab expected Q2 2026; EMA H2 2026), which supports liquidity and near-term value drivers. Read More.
• Positive Sentiment: Bullish analyst activity: Citigroup cut its price target slightly (to $41) but kept a Buy rating, and HC Wainwright reaffirmed Buy with a $44 target — both signal continued upside expectations from some sell‑side desks and likely helped intraday buying. Read More.
• Positive Sentiment: Insider buying and institutional accumulation highlighted in recent data — sustained insider purchases and notable increases from institutional holders suggest conviction from insiders and some large investors. Read More.
• Neutral Sentiment: Inducement grants: the company granted 235,700 options and 33,450 RSUs to new hires to aid recruitment — supports growth plans but introduces potential future dilution as grants vest. Read More.
• Neutral Sentiment: Morgan Stanley moved its price target up to $21 but kept an Equal Weight/Hold stance — a mixed signal that marginally improves analyst outlook yet sits below the current market price. Read More.
• Negative Sentiment: Major earnings miss: Zenas reported GAAP EPS of -$4.54 vs. consensus -$1.22, a significant shortfall that raises near-term profitability and execution concerns and pressures valuation. Read More.
• Negative Sentiment: Legal risk: disclosure of an IPO‑related securities class action remains an ongoing financial and operational risk that could create litigation cost and distraction. Read More.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.